3:34 PM
Feb 02, 2017
 |  BC Extra  |  Company News

Cytokinetics strikes royalty deal for omecamtiv mecarbil

Cytokinetics Inc. (NASDAQ:CYTK) is to receive $100 million in a deal with Royalty Pharma (New York, N.Y.) for royalties tied to heart failure candidate omecamtiv mecarbil (AMG 423). The biotech also said it will exercise an option under its deal with Amgen Inc. (NASDAQ:AMGN) allowing it to invest $40 million in the candidate's Phase III development, co-promote the candidate...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >